Kiniksa Pharmaceuticals Conference Call Summary Company Overview - **Company**: Kiniksa Pharmaceuticals International (NasdaqGS: KNSA) - **Event**: FY Conference on March 02, 2026 - **Key Speakers**: Sanj Patel (Chairman and CEO), Ross Moat (COO), John Paolini (CMO) Key Points Industry and Product Focus - **Primary Product**: ARCALYST, an IL-1 alpha and beta inhibitor for treating recurrent pericarditis - **Market Opportunity**: 18% penetration in the multiple recurrence patient group, with a total target market of 14,000 patients with multiple recurrences and an additional 26,000 patients experiencing their first recurrence [4][20][21] Financial Performance - **2025 Revenue**: Cumulative net revenue of $677.6 million, representing a 62% year-over-year growth [4] - **2026 Guidance**: Expected cumulative net revenue of $920 million, indicating continued growth [6] Growth Drivers - **Key Growth Factors**: - Increased patient additions and prescriber engagement - Higher rates of repeat prescriptions from physicians - Improved understanding of recurrent pericarditis as a chronic condition, leading to longer treatment durations [5][25] - Strong payer approval rates supporting commercial fundamentals [5] Marketing and Sales Strategy - **Sales Strategy**: Focus on digital marketing and AI initiatives to enhance prescriber education and patient engagement [19][36] - **Prescriber Engagement**: Over 4,150 unique prescribers identified, with a goal to reach the estimated 20,000-30,000 prescribers treating recurrent pericarditis [34] Treatment Paradigm Shift - **Changing Treatment Approaches**: Physicians are increasingly viewing recurrent pericarditis as a chronic condition requiring long-term treatment rather than episodic care [25][39] - **ARCALYST's Role**: Positioned as a preferred treatment option after NSAIDs and colchicine, especially for patients with severe symptoms or risk factors [39][40] Pipeline Developments - **KPL-387**: Phase 2 data expected in the second half of 2026, with plans to move into Phase 3 based on positive outcomes [59][60] - **KPL-1161**: Ongoing development with potential for indication expansion, though details remain undisclosed [72][74] Cash Flow and Investment Strategy - **Cash Utilization**: Focus on expanding KPL-387 and KPL-1161, while also considering potential acquisitions to enhance the portfolio [76][77] - **Pragmatic Approach**: The company emphasizes careful capital allocation and value creation, having successfully divested non-core assets in the past [77][78] Investor Insights - **Underappreciated Aspects**: The growth potential of KPL-387 and KPL-1161, along with the sustained success of ARCALYST, are highlighted as key areas that investors may overlook [79] Additional Considerations - **Q1 Expectations**: Anticipated headwinds due to payer plan changes and co-pay resets typical for the first quarter, which may impact gross-to-net revenue [28][31] - **Patient Characteristics**: Ongoing research into identifying patients who may benefit from early intervention with ARCALYST based on risk factors [51][52] This summary encapsulates the critical insights from the Kiniksa Pharmaceuticals conference call, focusing on the company's performance, strategic initiatives, and market opportunities.

Core Insights - The revenue growth of ARCALYST is projected at 62% for the full year 2025, driven by increased adoption of IL-1 alpha and beta inhibition as a second-line treatment after NSAID and colchicine failure [1] - Management credits the commercial success to a shift in treatment paradigms, supported by the 2025 ACC clinical guidance that endorses IL-1 inhibition as a preferred second-line approach [1] - The company is utilizing its profitable ARCALYST franchise to fund strategic investments in digital marketing, AI-driven physician targeting, and the development of internally discovered assets [1] Operational Focus - The operational focus has shifted towards unlocking the next phase of growth by increasing penetration in the multiple recurrence market and expanding into the first recurrence population [1] - Strategic positioning in the recurrent pericarditis market is being enhanced through the development of KPL-387, which aims to meet patient needs with less frequent monthly dosing and auto-injector administration [1] Market Dynamics - Market dynamics indicate that growth at specialized pericardial disease centers is outpacing other sites, leading management to explore ways to expand the impact of these high-volume centers [1]

Core Insights - Kiniksa Pharmaceuticals is focusing on expanding the adoption of ARCALYST for recurrent pericarditis, with plans for physician education and marketing initiatives to support earlier use in the disease course [1][4] - The company has set a net revenue guidance of $900 million to $920 million for 2026, despite facing seasonal headwinds in the specialty drug sector [2] - ARCALYST product revenue saw a significant increase of 65% year-over-year to $202.1 million in Q4 2025, contributing to a full-year revenue of $677.6 million, marking the highest year-on-year growth to date [3][14] Commercial Performance - The number of prescribers for ARCALYST exceeded 4,150 by the end of 2025, with approximately 29% prescribing it for two or more recurrent pericarditis patients [4] - Market penetration for the two-plus recurrence target market rose to about 18% by the end of 2025, up from 15% mid-year and 13% at the end of 2024 [5] - Approximately 20% of ARCALYST prescriptions are now written after a first recurrence, indicating a shift towards earlier treatment [6] Pipeline Developments - Kiniksa initiated a phase II/III clinical trial for KPL-387 in recurrent pericarditis in mid-2025, with phase II data expected in the second half of 2026 [7][8] - KPL-387 aims to enhance market penetration through monthly dosing with an auto-injector, with 75% of recurrent pericarditis patients preferring its target product profile [11] - KPL-1161, an Fc-modified IL-1 alpha and beta inhibitor, is expected to enter clinical trials by the end of 2026 [12] Financial Overview - Kiniksa reported a net income of $14.2 million in Q4 2025, a turnaround from a net loss of $8.9 million in the prior-year quarter, with a full-year net income of $59.0 million compared to a net loss of $43.2 million in 2024 [14] - Operating expenses increased due to higher costs associated with ARCALYST growth and investments in commercialization [13] - The company ended 2025 with $414.1 million in cash, indicating strong liquidity and a positive cash flow outlook [15]